ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Restricted Cash
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Restricted Cash of -$934.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-02-21
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for the quarter ending 2017-12-31 was $287.00K.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for the quarter ending 2017-09-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for the quarter ending 2017-06-30 was -$1.00K.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for the quarter ending 2017-03-31 was -$1.22M, a 179.07% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for fiscal 2017 was -$934.00K, a 177.70% decline from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for fiscal 2016 was $1.20M, a 22.00% decline from fiscal 2015.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for fiscal 2015 was $1.54M, a 425.94% increase from fiscal 2014.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in restricted cash for fiscal 2014 was $293.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month | Increase (Decrease) in Restricted Cash 47 month |
|---|---|---|---|---|---|
| 2017-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $287.00K derived: sum of 2 quarters · filed 2018-02-21 | $286.00K derived: sum of 3 quarters · filed 2018-02-21 | -$934.00K 10-K · filed 2018-02-21 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$1.00K derived: sum of 2 quarters · filed 2017-11-03 | -$1.22M 10-Q · filed 2017-11-03 | -$1.22M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2017-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$1.22M 10-Q · filed 2017-07-28 | -$1.22M derived: sum of 3 quarters · filed 2018-02-21 | -$1.56M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2017-03-31 | -$1.22M 10-Q · filed 2017-05-05 | -$1.22M derived: sum of 2 quarters · filed 2018-02-21 | -$1.56M derived: sum of 3 quarters · filed 2018-02-21 | -$1.56M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$341.00K derived: sum of 2 quarters · filed 2018-02-21 | -$341.00K derived: sum of 3 quarters · filed 2018-02-21 | $1.20M 10-K · filed 2018-02-21 | |
| 2016-09-30 | -$341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$341.00K derived: sum of 2 quarters · filed 2017-11-03 | $1.20M 10-Q · filed 2017-11-03 | $2.58M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $1.54M 10-Q · filed 2017-07-28 | $2.92M derived: sum of 3 quarters · filed 2018-02-21 | $1.84M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-03-31 | $1.54M 10-Q · filed 2017-05-05 | $2.92M derived: sum of 2 quarters · filed 2018-02-21 | $1.84M derived: sum of 3 quarters · filed 2018-02-21 | $1.73M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2015-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $302.00K derived: sum of 2 quarters · filed 2018-02-21 | $183.00K derived: sum of 3 quarters · filed 2018-02-21 | $1.54M 10-K · filed 2018-02-21 | |
| 2015-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$1.19M derived: sum of 2 quarters · filed 2015-11-10 | $168.00K 10-Q · filed 2015-11-10 | $168.00K derived: sum of 4 quarters · filed 2016-02-26 | |
| 2015-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.24M 10-Q · filed 2015-08-14 | $1.24M derived: sum of 3 quarters · filed 2016-02-26 | $1.24M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2015-03-31 | $1.36M 10-Q · filed 2015-05-12 | $1.36M derived: sum of 2 quarters · filed 2016-02-26 | $1.36M derived: sum of 3 quarters · filed 2016-02-26 | $1.36M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $0.00 derived: sum of 2 quarters · filed 2016-02-26 | $0.00 derived: sum of 3 quarters · filed 2016-02-26 | $293.00K 10-K · filed 2016-02-26 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $293.00K 10-Q · filed 2015-11-10 | $293.00K derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $293.00K 10-Q · filed 2015-08-14 | $293.00K derived: sum of 3 quarters · filed 2016-02-26 | $218.00K derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $293.00K 10-Q · filed 2015-05-12 | $293.00K derived: sum of 2 quarters · filed 2016-02-26 | $218.00K derived: sum of 3 quarters · filed 2016-02-26 | $744.00K 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$75.00K derived: sum of 2 quarters · filed 2016-02-26 | -$25.00K 10-K · filed 2016-02-26 | ||
| 2013-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$25.00K 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | $50.00K 10-Q · filed 2014-08-11 | ||||
| 2012-12-31 | $100.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |